Background: Improvement in blood flow is essential for the treatment of chronic limb-threatening ischemia. Historically, low-density lipoprotein apheresis has been employed as a treatment for peripheral blood flow and dyslipidemia. The introduction of a novel kind of low-density lipoprotein apheresis in 2021 has provided a more accessible and repeatable treatment option. However, there have been very few reports of novel kind of low-density lipoprotein apheresis for chronic limb-threatening ischemia.
Methods: Nineteen patients (Rutherford grade 5, 10 cases; Rutherford grade 6, 9 cases) treated with novel kind of low-density lipoprotein apheresis were included in this study. Four weeks after the initiation of treatment, the condition of the wounds was assessed.
Results: The number of treatment sessions ranged from 2 to 22 (mean 9.8 ± 6.3). Eleven out of 19 cases (57.9%) were assessed as “good”, including 80.0% (8/10) of the Rutherford 5 cases and 33.3% (3/9) of the Rutherford 6 cases. Those cases assessed as poverty-poor included five cases of disease progression leading to major amputation (Rutherford 5, 1 case; Rutherford 6, 4 cases) and three cases of treatment interruption by patient request. Apart from significantly lowered blood pressure in 11 cases, bleeding was the only adverse event observed, being seen in 2 cases.
Conclusions: Given its simple implementation and therapeutic effectiveness, novel kind of low-density lipoprotein apheresis should be considered as a treatment option for chronic limb-threatening ischemia. Initiation of such treatment at the early stage of Rutherford stage 5 yielded positive results.
(A) At the time of hospitalization. (B) Before skin graft. (C) Four months after skin graft.
View full abstract